|Home | About | Journals | Submit | Contact Us | Français|
Patients with moderate to severe Crohn's disease who had achieved remission after a four week regimen of the cytokine inhibitor adalimumab (CLASSIC I trial) went on to a placebo controlled trial of maintenance treatment for a year. Those who had not responded received the drug on an open-label basis. Of the 55 patients randomised, 8/18 who received placebo were in remission at 56 weeks compared with 15/19 who received adalimumab 40 mg subcutaneously every other week and 15/18 who received it weekly. The remission rate at 56 weeks in the remaining 204 patients, who had not responded at four weeks, was 46%. Treated patients were more likely to have reduced their corticosteroid dose and have an improved quality of life.
Adverse events were commoner with placebo than active drug, the most usual being upper respiratory symptoms. The investigators conclude that adalimumab is an important new therapeutic agent (currently not licensed for treating Crohn's disease in the UK).